Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China

Fineline Cube Aug 7, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...

Company Deals

Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil

Fineline Cube Aug 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...

Company Deals

Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079

Fineline Cube Aug 7, 2024

Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...

Company

Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare

Fineline Cube Aug 7, 2024

Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment

Fineline Cube Aug 6, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...

Company Medical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

Fineline Cube Aug 6, 2024

Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...

Company Drug

Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Fineline Cube Aug 6, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Aug 6, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Drug

Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar

Fineline Cube Aug 6, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...

Company Drug

Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment

Fineline Cube Aug 6, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...

Company Drug

CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment

Fineline Cube Aug 6, 2024

China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...

Company Deals

Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan

Fineline Cube Aug 6, 2024

Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire...

Company Deals

Sihuan Pharmaceutical Gains Exclusive Rights to Cellontech’s Cartilage Treatment in China

Fineline Cube Aug 6, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has entered...

Company Drug

Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China

Fineline Cube Aug 6, 2024

Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has...

Company Deals

BioNTech Ends Collaboration with Genmab on Acasunlimab Development

Fineline Cube Aug 6, 2024

Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech...

Company

Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling

Fineline Cube Aug 6, 2024

Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results...

Company

Daiichi Sankyo Reports 24.3% YOY Revenue Growth, Driven by Enhertu and Lixiana

Fineline Cube Aug 6, 2024

Daiichi Sankyo (TYO: 4568), a leading pharmaceutical company in Japan, reported a significant year-on-year (YOY)...

Company Drug

Shionogi Files for Chinese Approval of Cefiderocol to Combat Gram-Negative Bacterial Infections

Fineline Cube Aug 6, 2024

Shionogi Co., Ltd, a prominent Japanese pharmaceutical company, has announced the filing of a New...

Company Deals

Genor Biopharma Strikes Licensing Deal with TRC 2004 for Global Rights to GB261 Outside Greater China

Fineline Cube Aug 5, 2024

China-based Genor Biopharma Co., Ltd (HKG: 6998) has entered into a significant licensing and equity...

Company Drug

Degen Biopharmaceutical’s DG01 PROTAC Drug Receives NMPA Clearance for Solid Tumor Studies

Fineline Cube Aug 5, 2024

Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in...

Posts pagination

1 … 265 266 267 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.